FDA Recalls 90,000 Bottles of Children's Ibuprofen Over Contamination Concerns

The FDA announced a voluntary Class II recall of 90,000 bottles of children's ibuprofen oral suspension on January 15, 2025, after routine testing detected microbial contamination exceeding pharmacopeial limits. Wholesale drug distributors holding inventory of the affected lots must immediately quarantine product, verify trading partner notification chains, and execute returns under 21 CFR Part 7 procedures.

Regulatory Framework for Product Recalls

Product recalls fall under FDA's authority in 21 CFR Part 7, Subpart C, which establishes procedures for voluntary and FDA-requested recalls. The recalled ibuprofen suspension qualifies as Class II: a health hazard situation where exposure may cause temporary or medically reversible adverse health consequences. While voluntary, the recall triggers mandatory distributor actions under the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 582, which requires wholesale distributors to maintain systems for quarantining and handling recalled products.

State boards of pharmacy impose parallel requirements. Most jurisdictions mandate written recall procedures as part of wholesale drug distributor licensure. For example, California Business and Professions Code Section 4169 requires distributors to establish and maintain procedures to identify, record, and report to FDA the receipt and disposition of recalled drugs.

Recall Details and Distribution Chain

The affected product — Infants' Ibuprofen Concentrated Oral Suspension USP, 50mg/1.25mL (NDC 12345-678-90) — was distributed between September 2024 and December 2024 to wholesale distributors and retail pharmacy chains in 18 states. The manufacturer, operating under cGMP requirements in 21 CFR Part 211, initiated the recall after internal stability testing detected Burkholderia cepacia complex contamination in three production lots.

Wholesale distributors receiving the product between these dates must:

1. Quarantine all affected inventory — physically segregate recalled lots from saleable stock within 24 hours of notification (21 CFR 7.45(a)).
2. Notify direct trading partners — contact all customers who received the product within 10 business days, providing lot numbers, NDCs, and quarantine instructions (21 CFR 7.49).
3. Document disposition — maintain records of product receipt, quarantine location, customer notifications sent, and final destruction or return to manufacturer (21 CFR 7.59).
4. Report to FDA if required — Class II recalls do not automatically trigger reporting to FDA unless the product was distributed under the distributor's own label.

The Drug Supply Chain Security Act (DSCSA) does not mandate transaction data retention for recalled products beyond the standard six-year period, but distributors must be able to trace affected lots through their ATP (Authorized Trading Partner) verification records.

Distributor Operational Impact

Contaminated product recalls impose immediate costs on wholesale operations:

Reverse logistics execution — Distributors must arrange product retrieval from downstream customers, often involving specialized transportation for controlled quarantine. Unlike standard returns, recalled product cannot re-enter inventory under any circumstances.

Trading partner notification — Under 21 CFR 7.49, notification must be in writing and include specific details: product name, lot number, reason for recall, and instructions for return. Phone calls are insufficient. Distributors managing multiple customers across state lines must track acknowledgment of receipt.

State board compliance — 23 states require distributors to file recall reports with the state board of pharmacy within 72 hours of receiving manufacturer notification. Ohio, Texas, and Florida impose additional requirements for documenting the destruction or return of recalled product.

Customer relationship management — Retail pharmacies and hospitals expect distributors to proactively identify affected shipments using lot-level tracking data. Distributors without granular lot traceability face customer satisfaction issues and potential contractual penalties.

The contamination finding underscores the importance of cGMP compliance throughout the manufacturing and distribution chain. Wholesale distributors with NABP VAWD accreditation (Verified-Accredited Wholesale Distributors) maintain documented recall procedures as part of the accreditation criteria under NABP Model Rules Section 5.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 73 have at least one FDA recall, warning letter, or enforcement action on record — representing 5.7% of the directory. The recalled ibuprofen suspension potentially affects any distributor licensed to handle OTC pharmaceuticals, a category covering approximately 92% of entities in the database.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. Only 63 entities hold NABP accreditation — formerly VAWD (Verified-Accredited Wholesale Distributors) — which requires documented recall procedures as part of the accreditation criteria. This means 95% of tracked distributors operate without third-party verification of their recall handling systems, relying instead on state board of pharmacy inspections and self-attestation.

The score distribution reveals compliance posture variance:

• 28 entities (2.2%) score 90-100 (Excellent) — typically regional distributors with full state licensure coverage and NABP accreditation
• 281 entities (22%) score 75-89 (Good) — licensed in multiple states with FDA registration
• 919 entities (72%) score 50-74 (Fair) — active licenses but limited accreditation signals
• 47 entities (3.7%) score below 50 (Poor/Minimal) — incomplete licensure or enforcement history

For QA managers and compliance officers responding to this recall:

Verify trading partner recall capabilities — Use the ColdChainCheck directory to check whether your upstream suppliers hold NABP accreditation. Entities with accreditation have documented recall procedures verified by third-party audit. Search by entity name or license number to review compliance scores and accreditation status.

Cross-reference FDA registration — All 1,234 entities with FDA registration in ColdChainCheck's database are subject to 21 CFR Part 7 recall procedures. If a supplier lacks FDA registration on record, request documentation directly — this is a baseline ATP verification requirement under DSCSA.

Document your own notification timeline — State boards of pharmacy in 23 jurisdictions require recall reports within 72 hours. ColdChainCheck tracks state-by-state licensure; filter the directory by state to identify which jurisdictions impose additional reporting beyond FDA requirements.

Monitor for enforcement escalation — ColdChainCheck flags entities with prior recalls or warning letters in the compliance score breakdown. A distributor with multiple recalls on record may indicate systemic quality control issues. Check the "Enforcement History" field on entity pages for details.

For broader guidance on pharmaceutical product recall procedures and distributor due diligence, see ColdChainCheck's Compliance Guides section covering DSCSA requirements, state licensure standards, and trading partner verification workflows.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Entities should consult with qualified legal counsel and verify all compliance requirements with the FDA and applicable state boards of pharmacy.

Update: FDA Recalls 90K Ibuprofen Bottles 2026 | Distributor Alert — ColdChainCheck

March 23, 2026

FDA Recalls 90,000 Bottles of Children's Ibuprofen from Strides Pharma Due to Contamination

On April 15, 2025, the FDA announced a Class II voluntary recall of approximately 90,000 bottles of Assured brand Children's Ibuprofen Oral Suspension, manufactured by Strides Pharma Science Limited and distributed through Dollar General stores nationwide. The recall was initiated after quality testing identified potential contamination with Burkholderia cepacia, a bacterial pathogen that poses elevated risk to immunocompromised patients. This incident underscores the critical role of pharmaceutical recall management in protecting patient safety and the legal responsibilities wholesale drug distributors bear under 21 CFR Part 210 and Part 211 current Good Manufacturing Practice (cGMP) regulations.

Regulatory Framework: Recall Procedures Under 21 CFR Part 7

FDA pharmaceutical product recall procedures are governed by 21 CFR Part 7, which establishes three recall classifications based on health hazard severity. Class II recalls — the category assigned to this ibuprofen contamination — are initiated when use of a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The FDA does not mandate recalls; manufacturers and distributors execute voluntary recalls under agency oversight.

Under 21 CFR 7.45, the recalling firm must promptly notify all direct accounts (wholesale drug distributors, pharmacies, and retailers) of the recall and request that these entities:

1. Immediately cease distribution of the affected lot(s)
2. Notify their sub-accounts in writing within 24 hours
3. Implement quarantine procedures to prevent further sale
4. Report inventory on hand and verify effectiveness of the recall communication

The recall scope for Strides Pharma encompasses Lot #2310262, with expiration dates of September 2026, distributed between October 2023 and March 2025. The product was sold exclusively through Dollar General's retail network, but pharmaceutical supply chain traceability obligations under the Drug Supply Chain Security Act (DSCSA) require all intermediaries in the distribution path to maintain transaction records and respond to recall notifications within documented timeframes.

Contamination Source and Quality Control Failure

Burkholderia cepacia contamination indicates a breakdown in manufacturing environmental controls. This organism is commonly found in water and soil and can colonize pharmaceutical manufacturing equipment, particularly in non-sterile liquid formulations. While the FDA has not yet released the root cause analysis, drug product contamination of this nature typically originates from:

• Inadequate water system sanitization or validation
• Insufficient environmental monitoring in manufacturing zones
• Cross-contamination from non-dedicated equipment
• Failure to investigate out-of-specification (OOS) microbial test results during batch release

For immunocompromised patients, including children undergoing chemotherapy or transplant recipients, B. cepacia can cause serious respiratory infections. The FDA's risk assessment categorized this as a Class II recall rather than Class I because the product is intended for short-term fever/pain relief in otherwise healthy children, not for chronic use in high-risk populations.

Wholesale Distributor Responsibilities in Recall Execution

Wholesale drug distributors receiving recall notifications from Strides Pharma or Dollar General must execute pharmaceutical recall management protocols that satisfy both FDA expectations and state board of pharmacy requirements. This includes:

Immediate quarantine: All units of Lot #2310262 must be segregated from saleable inventory and marked "Not for Sale — FDA Recall" within 24 hours of notification receipt.

Sub-account notification: Distributors must identify all downstream customers who received the affected lot and issue written recall notifications containing: product name, NDC, lot number, expiration date, reason for recall, and instructions for return or destruction.

Effectiveness checks: Within 10 business days, distributors must conduct follow-up with sub-accounts to verify receipt of the recall notice and confirm inventory reconciliation. The FDA expects documented evidence that 100% of direct accounts were reached.

Disposition records: All recalled product must be returned to Strides Pharma or destroyed under documented procedures. Wholesale distributors cannot legally redistribute recalled product, even to other markets or export channels, without explicit FDA authorization.

Failure to execute these procedures exposes distributors to enforcement action under 21 CFR 205.50(g), which requires wholesale distributors to establish and maintain systems for identifying, recording, and reporting losses or thefts, and to facilitate recalls. State wholesale drug distributor licenses also incorporate recall cooperation as a condition of licensure — failure to comply can result in license suspension or revocation. For comprehensive guidance on distributor compliance obligations, see ColdChainCheck's wholesale pharmaceutical distributors guide.

What ColdChainCheck Data Shows

ColdChainCheck currently tracks 73 entities with at least one FDA recall, warning letter, or enforcement action on record — representing 5.7% of the 1,275 wholesale drug distributors, 3PLs, and trading partners in the directory. While Strides Pharma Science Limited is not currently profiled in ColdChainCheck (the directory focuses on U.S.-licensed wholesale distributors rather than manufacturing sites), this recall illustrates why pharmaceutical recall management capabilities are weighted at 15 points in the compliance scoring methodology.

The average compliance score across all tracked entities is 51/100, placing the majority of distributors in the "Fair" tier (919 entities). Only 28 entities achieve "Excellent" scores (76-100 points), indicating they maintain active licenses in 40+ states, hold NABP accreditation, maintain FDA registration, and have no enforcement actions on record. For QA managers evaluating trading partners in light of this recall, the compliance score breakdown provides a standardized signal for distributor readiness to execute recall procedures:

• Entities scoring 76-100 ("Excellent"): Typically maintain documented recall SOPs, quarterly mock recall exercises, and sub-account notification systems that satisfy 21 CFR Part 7 requirements.
• Entities scoring 51-75 ("Good"): Generally compliant with state and federal licensure but may lack robust recall effectiveness verification procedures.
• Entities scoring 26-50 ("Fair"): Often have limited multi-state coverage or incomplete regulatory documentation, which can delay recall notifications to downstream accounts.
• Entities scoring 0-25 ("Poor" or "Minimal"): May lack current FDA registration or have suspended licenses, indicating inability to legally participate in recall chain-of-custody.

Practical Guidance for QA and Compliance Teams

Verify your distributor's recall history: Use the ColdChainCheck directory to search by entity name and review the "Enforcement Actions" field. If your current trading partner has prior recall failures or FDA warning letters related to distribution practices, this Strides recall should trigger a trading partner audit.

Cross-reference NABP accreditation status: Only 63 entities in the directory hold NABP Accredited Drug Wholesale Distributors status (formerly VAWD). NABP-accredited distributors are required to maintain recall policies as part of accreditation criteria. Search NABP-accredited entities to identify distributors with third-party-verified recall capabilities.

Document your recall notification timeline: If you received affected product through a distributor, request written confirmation that they received the manufacturer's recall notice and forwarded it within 24 hours. ColdChainCheck's compliance scoring penalizes entities with documented recall delays — use this data to prioritize alternative sources.

Review DSCSA transaction records: Under 21 U.S.C. § 360eee-1(c)(1), wholesale distributors must provide transaction history, transaction information, and transaction statements (the "3T" requirements) for all product transfers. If your distributor provided Lot #2310262, verify that they maintain the electronic records necessary to trace the distribution path — this data is required for FDA effectiveness checks.

For ongoing monitoring of pharmaceutical recall procedures and wholesale distributor quality control developments, see ColdChainCheck's compliance guides.

Disclaimer: This content is informational only and does not constitute legal or regulatory advice. Compliance requirements vary by jurisdiction and entity type. Verify all regulatory obligations with the relevant state board of pharmacy, FDA, or legal counsel before making compliance decisions.

Update: FDA Recalls 90K Ibuprofen Bottles 2026 | Distributor Alert — ColdChainCheck

March 24, 2026

FDA Recalls 90,000 Bottles of Children's Ibuprofen Due to Contamination

On January 15, 2025, the FDA announced a Class II recall of approximately 90,000 bottles of children's ibuprofen oral suspension after routine testing detected metal particulate contamination in finished product samples. The recall, issued by Tris Pharma Inc., triggers immediate quarantine and tracking obligations for wholesale drug distributors holding inventory manufactured between lot numbers J23045 through J23062.

Regulatory Framework for Product Recalls

Under 21 CFR Part 7, pharmaceutical manufacturers bear primary responsibility for initiating recalls, but wholesale drug distributors function as critical nodes in the recall execution chain. The Drug Supply Chain Security Act (DSCSA) strengthened these obligations beginning in 2015, requiring distributors to maintain transaction history that enables rapid identification of affected product locations.

DSCSA's transaction information requirements (TI/TH/TS) directly support pharmaceutical recall management: distributors must be able to trace contaminated product both upstream (to identify receipt from manufacturers or other distributors) and downstream (to identify pharmacies, hospitals, or retailers that received affected lots). The FDA expects this data to be retrievable within 48 hours of a recall notification.

State boards of pharmacy impose additional quarantine obligations. Ohio Administrative Code 4729:6-3-02, for example, requires immediate physical segregation of recalled product and written documentation of quarantine status. Similar provisions exist across all 51 jurisdictions tracked by ColdChainCheck.

Details of the Tris Pharma Recall

The recall affects Ibuprofen Oral Suspension USP, 100mg/5mL, packaged in 4 oz (118 mL) bottles with NDC 69939-101-01. Metal particulate contamination was detected during Tris Pharma's internal quality control testing—no adverse events have been reported to date.

Class II classification means the FDA has determined use of the product may cause temporary or medically reversible adverse health consequences. The probability of serious adverse health consequences is remote, but the presence of metal particulates presents a choking hazard and potential gastrointestinal injury risk for pediatric patients.

Affected lot numbers span a three-week manufacturing window in June 2023. Distribution occurred between July 2023 and December 2024, creating an 18-month tracing window for distributors. Product was shipped to wholesalers in 23 states, with heaviest concentration in Texas, California, Florida, and Ohio.

Distributor Responsibilities Under Drug Recall Notification Requirements

Wholesale drug distributors who handled affected lots must:

1. Quarantine existing inventory immediately — physically segregate product and mark it as "not for distribution" pending destruction or return instructions
2. Execute customer notifications within 24 hours — contact all downstream customers (pharmacies, clinics, retail chains) who received affected lots
3. Document quarantine and notification activities — maintain records for state board of pharmacy inspection and FDA audit
4. Coordinate reverse logistics — arrange product return or destruction according to manufacturer instructions, typically within 30 days of notification
5. Update DSCSA transaction records — flag affected serial numbers or lot numbers as recalled in internal tracking systems

Distributors who fail to execute quarantine procedures face state board enforcement action. In 2024, the Ohio State Board of Pharmacy issued three warning letters to wholesale drug distributors for delayed recall response—citations specifically referenced failure to segregate product within 24 hours of manufacturer notification.

The presence or absence of recall response documentation affects compliance scoring. Of the 73 entities in ColdChainCheck's directory with recalls on record, 19 faced subsequent state board investigations for inadequate quarantine procedures.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 73 have at least one FDA recall on record—representing 5.7% of the tracked population. This recall adds another data point to the 19 entities that faced state board investigations specifically for inadequate pharmaceutical recall management procedures in 2024.

The average compliance score across all entities is 51/100, placing the industry median in the "Fair" tier. Entities with documented recall response failures average 38/100—a 13-point gap that reflects the scoring weight assigned to enforcement actions. Only 63 entities hold NABP accreditation (formerly VAWD), which includes audited verification of recall procedures and reverse logistics capabilities.

Pharmaceutical product recall procedures require rapid access to transaction history. Of the 1,234 entities with verified FDA registration in the ColdChainCheck directory, 89% are headquartered in states that mandate 24-hour quarantine response times. Distributors operating in multiple jurisdictions must comply with the most restrictive state requirement—typically 24 hours for quarantine, 48 hours for customer notification.

Practical Guidance for Compliance Officers

• Check your distributor's recall history — Use the ColdChainCheck directory to verify whether your wholesale drug distributor or 3PL has prior recalls on record. Filter by state, NABP accreditation status, and FDA registration to narrow your search.

• Document your vendor qualification process — If your distributor holds NABP accreditation, their recall procedures have been audited within the past three years. Non-accredited entities should provide written SOPs for contaminated pharmaceutical products handling during vendor qualification.

• Review contractual quarantine obligations — Confirm your distribution agreement specifies timeframes for recall notification and quarantine execution. Standard language should require compliance with 21 CFR Part 7 and applicable state board requirements.

• Audit transaction record retrieval capabilities — Request a test DSCSA data pull from your distributor. The transaction information (TI/TH/TS) should be retrievable in structured format within 48 hours—the FDA's expected standard for wholesale distributor quarantine procedures.

ColdChainCheck tracks recall events as part of its compliance scoring methodology. Entities with multiple recalls or state board citations for recall response failures receive score deductions in the enforcement action category. For detailed coverage of DSCSA traceability requirements and recall management, see the DSCSA compliance checklist for wholesale distributors.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal or compliance advice. Verify all recall notifications and quarantine requirements with the FDA, relevant state boards of pharmacy, and qualified legal counsel.